nodes	percent_of_prediction	percent_of_DWPC	metapath
Glyburide—ABCC3—Vincristine—lymphatic system cancer	0.0835	0.099	CbGbCtD
Glyburide—ABCC1—Mitoxantrone—lymphatic system cancer	0.0745	0.0883	CbGbCtD
Glyburide—ABCB11—Vincristine—lymphatic system cancer	0.0722	0.0855	CbGbCtD
Glyburide—ABCG2—Teniposide—lymphatic system cancer	0.0713	0.0845	CbGbCtD
Glyburide—ABCC1—Vincristine—lymphatic system cancer	0.0513	0.0608	CbGbCtD
Glyburide—ABCC3—Methotrexate—lymphatic system cancer	0.0506	0.0599	CbGbCtD
Glyburide—ABCG2—Mitoxantrone—lymphatic system cancer	0.0499	0.0591	CbGbCtD
Glyburide—SLC22A7—Methotrexate—lymphatic system cancer	0.0395	0.0469	CbGbCtD
Glyburide—ABCC2—Vincristine—lymphatic system cancer	0.0379	0.045	CbGbCtD
Glyburide—ABCG2—Vincristine—lymphatic system cancer	0.0343	0.0407	CbGbCtD
Glyburide—CYP2C19—Teniposide—lymphatic system cancer	0.0319	0.0378	CbGbCtD
Glyburide—ABCC1—Methotrexate—lymphatic system cancer	0.031	0.0368	CbGbCtD
Glyburide—SLCO1A2—Methotrexate—lymphatic system cancer	0.0277	0.0329	CbGbCtD
Glyburide—CYP2C9—Teniposide—lymphatic system cancer	0.0265	0.0314	CbGbCtD
Glyburide—ABCC2—Methotrexate—lymphatic system cancer	0.023	0.0272	CbGbCtD
Glyburide—ABCG2—Methotrexate—lymphatic system cancer	0.0208	0.0246	CbGbCtD
Glyburide—ABCB1—Mitoxantrone—lymphatic system cancer	0.018	0.0213	CbGbCtD
Glyburide—SLC22A6—Methotrexate—lymphatic system cancer	0.0168	0.0199	CbGbCtD
Glyburide—CYP3A4—Cytarabine—lymphatic system cancer	0.0156	0.0185	CbGbCtD
Glyburide—CYP3A4—Teniposide—lymphatic system cancer	0.0154	0.0183	CbGbCtD
Glyburide—ALB—Methotrexate—lymphatic system cancer	0.0143	0.017	CbGbCtD
Glyburide—ABCB1—Vincristine—lymphatic system cancer	0.0124	0.0147	CbGbCtD
Glyburide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0108	0.0128	CbGbCtD
Glyburide—ABCB1—Methotrexate—lymphatic system cancer	0.00749	0.00888	CbGbCtD
Glyburide—CYP3A4—Vincristine—lymphatic system cancer	0.00741	0.00879	CbGbCtD
Glyburide—Alopecia—Mechlorethamine—lymphatic system cancer	0.00118	0.00752	CcSEcCtD
Glyburide—Pancytopenia—Teniposide—lymphatic system cancer	0.00116	0.00744	CcSEcCtD
Glyburide—Nephropathy—Methotrexate—lymphatic system cancer	0.00107	0.00683	CcSEcCtD
Glyburide—Sweating increased—Fludarabine—lymphatic system cancer	0.00105	0.00671	CcSEcCtD
Glyburide—Leukocytoclastic vasculitis—Methotrexate—lymphatic system cancer	0.00104	0.00663	CcSEcCtD
Glyburide—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00104	0.00663	CcSEcCtD
Glyburide—Pancytopenia—Fludarabine—lymphatic system cancer	0.00102	0.00654	CcSEcCtD
Glyburide—Arthritis—Bleomycin—lymphatic system cancer	0.00094	0.00601	CcSEcCtD
Glyburide—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.000925	0.00592	CcSEcCtD
Glyburide—Anorexia—Mechlorethamine—lymphatic system cancer	0.000901	0.00576	CcSEcCtD
Glyburide—Alopecia—Teniposide—lymphatic system cancer	0.000866	0.00554	CcSEcCtD
Glyburide—Deafness—Vincristine—lymphatic system cancer	0.000851	0.00544	CcSEcCtD
Glyburide—Hepatic failure—Vincristine—lymphatic system cancer	0.000847	0.00542	CcSEcCtD
Glyburide—Visual impairment—Fludarabine—lymphatic system cancer	0.00083	0.00531	CcSEcCtD
Glyburide—Eruption—Methotrexate—lymphatic system cancer	0.000827	0.00529	CcSEcCtD
Glyburide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.000821	0.00525	CcSEcCtD
Glyburide—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.000803	0.00513	CcSEcCtD
Glyburide—Hyponatraemia—Carmustine—lymphatic system cancer	0.0008	0.00512	CcSEcCtD
Glyburide—Diplopia—Carmustine—lymphatic system cancer	0.000797	0.0051	CcSEcCtD
Glyburide—Encephalopathy—Methotrexate—lymphatic system cancer	0.000792	0.00507	CcSEcCtD
Glyburide—Anaemia—Teniposide—lymphatic system cancer	0.000789	0.00505	CcSEcCtD
Glyburide—Hyponatraemia—Vincristine—lymphatic system cancer	0.000764	0.00489	CcSEcCtD
Glyburide—Leukopenia—Teniposide—lymphatic system cancer	0.000764	0.00489	CcSEcCtD
Glyburide—Alopecia—Fludarabine—lymphatic system cancer	0.000761	0.00487	CcSEcCtD
Glyburide—Malnutrition—Fludarabine—lymphatic system cancer	0.00075	0.0048	CcSEcCtD
Glyburide—Pancytopenia—Bleomycin—lymphatic system cancer	0.00075	0.00479	CcSEcCtD
Glyburide—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.000744	0.00476	CcSEcCtD
Glyburide—Confusional state—Teniposide—lymphatic system cancer	0.000702	0.00449	CcSEcCtD
Glyburide—Oedema—Teniposide—lymphatic system cancer	0.000696	0.00446	CcSEcCtD
Glyburide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000696	0.00445	CcSEcCtD
Glyburide—Anaemia—Fludarabine—lymphatic system cancer	0.000693	0.00443	CcSEcCtD
Glyburide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000682	0.00436	CcSEcCtD
Glyburide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.000673	0.00431	CcSEcCtD
Glyburide—Leukopenia—Fludarabine—lymphatic system cancer	0.000671	0.00429	CcSEcCtD
Glyburide—Pruritus—Mechlorethamine—lymphatic system cancer	0.000668	0.00428	CcSEcCtD
Glyburide—Anorexia—Teniposide—lymphatic system cancer	0.000664	0.00425	CcSEcCtD
Glyburide—Pancytopenia—Carmustine—lymphatic system cancer	0.000654	0.00419	CcSEcCtD
Glyburide—Hypotension—Teniposide—lymphatic system cancer	0.000651	0.00416	CcSEcCtD
Glyburide—Convulsion—Fludarabine—lymphatic system cancer	0.00065	0.00416	CcSEcCtD
Glyburide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000646	0.00413	CcSEcCtD
Glyburide—Arthralgia—Fludarabine—lymphatic system cancer	0.000639	0.00408	CcSEcCtD
Glyburide—Myalgia—Fludarabine—lymphatic system cancer	0.000639	0.00408	CcSEcCtD
Glyburide—Pancytopenia—Vincristine—lymphatic system cancer	0.000625	0.004	CcSEcCtD
Glyburide—Sweating increased—Mitoxantrone—lymphatic system cancer	0.000624	0.00399	CcSEcCtD
Glyburide—Dyspnoea—Teniposide—lymphatic system cancer	0.000621	0.00397	CcSEcCtD
Glyburide—Confusional state—Fludarabine—lymphatic system cancer	0.000617	0.00395	CcSEcCtD
Glyburide—Oedema—Fludarabine—lymphatic system cancer	0.000612	0.00392	CcSEcCtD
Glyburide—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.000608	0.00389	CcSEcCtD
Glyburide—Decreased appetite—Teniposide—lymphatic system cancer	0.000605	0.00387	CcSEcCtD
Glyburide—Vomiting—Mechlorethamine—lymphatic system cancer	0.000601	0.00384	CcSEcCtD
Glyburide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.0006	0.00384	CcSEcCtD
Glyburide—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.0006	0.00384	CcSEcCtD
Glyburide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000599	0.00383	CcSEcCtD
Glyburide—Rash—Mechlorethamine—lymphatic system cancer	0.000596	0.00381	CcSEcCtD
Glyburide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000595	0.00381	CcSEcCtD
Glyburide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000592	0.00379	CcSEcCtD
Glyburide—Anorexia—Fludarabine—lymphatic system cancer	0.000583	0.00373	CcSEcCtD
Glyburide—Feeling abnormal—Teniposide—lymphatic system cancer	0.000574	0.00367	CcSEcCtD
Glyburide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00057	0.00364	CcSEcCtD
Glyburide—Nausea—Mechlorethamine—lymphatic system cancer	0.000561	0.00359	CcSEcCtD
Glyburide—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.000559	0.00358	CcSEcCtD
Glyburide—Alopecia—Bleomycin—lymphatic system cancer	0.000558	0.00357	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000558	0.00357	CcSEcCtD
Glyburide—Jaundice—Mitoxantrone—lymphatic system cancer	0.000557	0.00356	CcSEcCtD
Glyburide—Urticaria—Teniposide—lymphatic system cancer	0.000553	0.00354	CcSEcCtD
Glyburide—Abdominal pain—Teniposide—lymphatic system cancer	0.000551	0.00352	CcSEcCtD
Glyburide—Erythema—Bleomycin—lymphatic system cancer	0.00055	0.00352	CcSEcCtD
Glyburide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00055	0.00352	CcSEcCtD
Glyburide—Dyspnoea—Fludarabine—lymphatic system cancer	0.000546	0.00349	CcSEcCtD
Glyburide—Dyspepsia—Fludarabine—lymphatic system cancer	0.000539	0.00345	CcSEcCtD
Glyburide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000533	0.00341	CcSEcCtD
Glyburide—Decreased appetite—Fludarabine—lymphatic system cancer	0.000532	0.0034	CcSEcCtD
Glyburide—Visual impairment—Carmustine—lymphatic system cancer	0.000531	0.0034	CcSEcCtD
Glyburide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000528	0.00338	CcSEcCtD
Glyburide—Vasculitis—Methotrexate—lymphatic system cancer	0.000521	0.00333	CcSEcCtD
Glyburide—Eye disorder—Carmustine—lymphatic system cancer	0.000515	0.0033	CcSEcCtD
Glyburide—Hypersensitivity—Teniposide—lymphatic system cancer	0.000513	0.00328	CcSEcCtD
Glyburide—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000513	0.00328	CcSEcCtD
Glyburide—Anaemia—Bleomycin—lymphatic system cancer	0.000508	0.00325	CcSEcCtD
Glyburide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000504	0.00323	CcSEcCtD
Glyburide—Asthenia—Teniposide—lymphatic system cancer	0.0005	0.0032	CcSEcCtD
Glyburide—Pruritus—Teniposide—lymphatic system cancer	0.000493	0.00315	CcSEcCtD
Glyburide—Leukopenia—Bleomycin—lymphatic system cancer	0.000492	0.00315	CcSEcCtD
Glyburide—Alopecia—Carmustine—lymphatic system cancer	0.000487	0.00312	CcSEcCtD
Glyburide—Erythema—Carmustine—lymphatic system cancer	0.00048	0.00307	CcSEcCtD
Glyburide—Malnutrition—Carmustine—lymphatic system cancer	0.00048	0.00307	CcSEcCtD
Glyburide—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000478	0.00305	CcSEcCtD
Glyburide—Diarrhoea—Teniposide—lymphatic system cancer	0.000477	0.00305	CcSEcCtD
Glyburide—Myalgia—Bleomycin—lymphatic system cancer	0.000468	0.00299	CcSEcCtD
Glyburide—Alopecia—Vincristine—lymphatic system cancer	0.000465	0.00298	CcSEcCtD
Glyburide—Alopecia—Mitoxantrone—lymphatic system cancer	0.000453	0.0029	CcSEcCtD
Glyburide—Confusional state—Bleomycin—lymphatic system cancer	0.000453	0.00289	CcSEcCtD
Glyburide—Vision blurred—Carmustine—lymphatic system cancer	0.000452	0.00289	CcSEcCtD
Glyburide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000451	0.00288	CcSEcCtD
Glyburide—Tremor—Carmustine—lymphatic system cancer	0.00045	0.00288	CcSEcCtD
Glyburide—Oedema—Bleomycin—lymphatic system cancer	0.000449	0.00287	CcSEcCtD
Glyburide—Erythema—Mitoxantrone—lymphatic system cancer	0.000446	0.00285	CcSEcCtD
Glyburide—Anaemia—Carmustine—lymphatic system cancer	0.000444	0.00284	CcSEcCtD
Glyburide—Vomiting—Teniposide—lymphatic system cancer	0.000443	0.00283	CcSEcCtD
Glyburide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000439	0.00281	CcSEcCtD
Glyburide—Asthenia—Fludarabine—lymphatic system cancer	0.000439	0.00281	CcSEcCtD
Glyburide—Rash—Teniposide—lymphatic system cancer	0.000439	0.00281	CcSEcCtD
Glyburide—Dermatitis—Teniposide—lymphatic system cancer	0.000439	0.00281	CcSEcCtD
Glyburide—Headache—Teniposide—lymphatic system cancer	0.000436	0.00279	CcSEcCtD
Glyburide—Pruritus—Fludarabine—lymphatic system cancer	0.000433	0.00277	CcSEcCtD
Glyburide—Leukopenia—Carmustine—lymphatic system cancer	0.00043	0.00275	CcSEcCtD
Glyburide—Anorexia—Bleomycin—lymphatic system cancer	0.000428	0.00274	CcSEcCtD
Glyburide—Anaemia—Vincristine—lymphatic system cancer	0.000424	0.00271	CcSEcCtD
Glyburide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000421	0.00269	CcSEcCtD
Glyburide—Hypotension—Bleomycin—lymphatic system cancer	0.000419	0.00268	CcSEcCtD
Glyburide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000419	0.00268	CcSEcCtD
Glyburide—Convulsion—Carmustine—lymphatic system cancer	0.000416	0.00266	CcSEcCtD
Glyburide—Nausea—Teniposide—lymphatic system cancer	0.000414	0.00265	CcSEcCtD
Glyburide—Anaemia—Mitoxantrone—lymphatic system cancer	0.000412	0.00264	CcSEcCtD
Glyburide—Hepatic failure—Methotrexate—lymphatic system cancer	0.000411	0.00263	CcSEcCtD
Glyburide—Leukopenia—Vincristine—lymphatic system cancer	0.00041	0.00262	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000409	0.00262	CcSEcCtD
Glyburide—Myalgia—Carmustine—lymphatic system cancer	0.000409	0.00261	CcSEcCtD
Glyburide—Paraesthesia—Bleomycin—lymphatic system cancer	0.000403	0.00258	CcSEcCtD
Glyburide—Dyspnoea—Bleomycin—lymphatic system cancer	0.0004	0.00256	CcSEcCtD
Glyburide—Renal failure acute—Methotrexate—lymphatic system cancer	0.0004	0.00256	CcSEcCtD
Glyburide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000399	0.00256	CcSEcCtD
Glyburide—Convulsion—Vincristine—lymphatic system cancer	0.000397	0.00254	CcSEcCtD
Glyburide—Confusional state—Carmustine—lymphatic system cancer	0.000395	0.00253	CcSEcCtD
Glyburide—Oedema—Carmustine—lymphatic system cancer	0.000392	0.00251	CcSEcCtD
Glyburide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00039	0.0025	CcSEcCtD
Glyburide—Myalgia—Vincristine—lymphatic system cancer	0.00039	0.0025	CcSEcCtD
Glyburide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00039	0.00249	CcSEcCtD
Glyburide—Vomiting—Fludarabine—lymphatic system cancer	0.000389	0.00249	CcSEcCtD
Glyburide—Convulsion—Mitoxantrone—lymphatic system cancer	0.000387	0.00247	CcSEcCtD
Glyburide—Rash—Fludarabine—lymphatic system cancer	0.000386	0.00247	CcSEcCtD
Glyburide—Dermatitis—Fludarabine—lymphatic system cancer	0.000386	0.00247	CcSEcCtD
Glyburide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000384	0.00245	CcSEcCtD
Glyburide—Headache—Fludarabine—lymphatic system cancer	0.000383	0.00245	CcSEcCtD
Glyburide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00038	0.00243	CcSEcCtD
Glyburide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00038	0.00243	CcSEcCtD
Glyburide—Oedema—Vincristine—lymphatic system cancer	0.000374	0.00239	CcSEcCtD
Glyburide—Anorexia—Carmustine—lymphatic system cancer	0.000373	0.00239	CcSEcCtD
Glyburide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00037	0.00237	CcSEcCtD
Glyburide—Confusional state—Mitoxantrone—lymphatic system cancer	0.000367	0.00235	CcSEcCtD
Glyburide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000367	0.00235	CcSEcCtD
Glyburide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000366	0.00234	CcSEcCtD
Glyburide—Hypotension—Carmustine—lymphatic system cancer	0.000366	0.00234	CcSEcCtD
Glyburide—Oedema—Mitoxantrone—lymphatic system cancer	0.000364	0.00233	CcSEcCtD
Glyburide—Nausea—Fludarabine—lymphatic system cancer	0.000364	0.00233	CcSEcCtD
Glyburide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000362	0.00231	CcSEcCtD
Glyburide—Shock—Mitoxantrone—lymphatic system cancer	0.000358	0.00229	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000357	0.00228	CcSEcCtD
Glyburide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000357	0.00228	CcSEcCtD
Glyburide—Urticaria—Bleomycin—lymphatic system cancer	0.000357	0.00228	CcSEcCtD
Glyburide—Anorexia—Vincristine—lymphatic system cancer	0.000356	0.00228	CcSEcCtD
Glyburide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000352	0.00225	CcSEcCtD
Glyburide—Paraesthesia—Carmustine—lymphatic system cancer	0.000352	0.00225	CcSEcCtD
Glyburide—Hypotension—Vincristine—lymphatic system cancer	0.000349	0.00224	CcSEcCtD
Glyburide—Dyspnoea—Carmustine—lymphatic system cancer	0.000349	0.00223	CcSEcCtD
Glyburide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000347	0.00222	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000341	0.00218	CcSEcCtD
Glyburide—Decreased appetite—Carmustine—lymphatic system cancer	0.000341	0.00218	CcSEcCtD
Glyburide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00034	0.00218	CcSEcCtD
Glyburide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000338	0.00216	CcSEcCtD
Glyburide—Paraesthesia—Vincristine—lymphatic system cancer	0.000336	0.00215	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000332	0.00212	CcSEcCtD
Glyburide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000331	0.00212	CcSEcCtD
Glyburide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000327	0.00209	CcSEcCtD
Glyburide—Decreased appetite—Vincristine—lymphatic system cancer	0.000325	0.00208	CcSEcCtD
Glyburide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000325	0.00208	CcSEcCtD
Glyburide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000323	0.00207	CcSEcCtD
Glyburide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000323	0.00207	CcSEcCtD
Glyburide—Asthenia—Bleomycin—lymphatic system cancer	0.000322	0.00206	CcSEcCtD
Glyburide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000321	0.00205	CcSEcCtD
Glyburide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00032	0.00205	CcSEcCtD
Glyburide—Pruritus—Bleomycin—lymphatic system cancer	0.000318	0.00203	CcSEcCtD
Glyburide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000317	0.00203	CcSEcCtD
Glyburide—Eosinophilia—Methotrexate—lymphatic system cancer	0.000316	0.00202	CcSEcCtD
Glyburide—Pancreatitis—Methotrexate—lymphatic system cancer	0.000313	0.002	CcSEcCtD
Glyburide—Abdominal pain—Carmustine—lymphatic system cancer	0.00031	0.00198	CcSEcCtD
Glyburide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000306	0.00196	CcSEcCtD
Glyburide—Pancytopenia—Methotrexate—lymphatic system cancer	0.000303	0.00194	CcSEcCtD
Glyburide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.0003	0.00192	CcSEcCtD
Glyburide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000298	0.00191	CcSEcCtD
Glyburide—Abdominal pain—Vincristine—lymphatic system cancer	0.000296	0.00189	CcSEcCtD
Glyburide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000291	0.00186	CcSEcCtD
Glyburide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000289	0.00185	CcSEcCtD
Glyburide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000289	0.00185	CcSEcCtD
Glyburide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000288	0.00184	CcSEcCtD
Glyburide—Vomiting—Bleomycin—lymphatic system cancer	0.000285	0.00183	CcSEcCtD
Glyburide—Rash—Bleomycin—lymphatic system cancer	0.000283	0.00181	CcSEcCtD
Glyburide—Dermatitis—Bleomycin—lymphatic system cancer	0.000283	0.00181	CcSEcCtD
Glyburide—Asthenia—Carmustine—lymphatic system cancer	0.000281	0.0018	CcSEcCtD
Glyburide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000276	0.00176	CcSEcCtD
Glyburide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000268	0.00172	CcSEcCtD
Glyburide—Asthenia—Vincristine—lymphatic system cancer	0.000268	0.00172	CcSEcCtD
Glyburide—Diarrhoea—Carmustine—lymphatic system cancer	0.000268	0.00171	CcSEcCtD
Glyburide—Nausea—Bleomycin—lymphatic system cancer	0.000267	0.00171	CcSEcCtD
Glyburide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000266	0.0017	CcSEcCtD
Glyburide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000261	0.00167	CcSEcCtD
Glyburide—Diarrhoea—Vincristine—lymphatic system cancer	0.000256	0.00164	CcSEcCtD
Glyburide—Hepatitis—Methotrexate—lymphatic system cancer	0.000255	0.00163	CcSEcCtD
Glyburide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000249	0.00159	CcSEcCtD
Glyburide—Vomiting—Carmustine—lymphatic system cancer	0.000249	0.00159	CcSEcCtD
Glyburide—Rash—Carmustine—lymphatic system cancer	0.000247	0.00158	CcSEcCtD
Glyburide—Dermatitis—Carmustine—lymphatic system cancer	0.000247	0.00158	CcSEcCtD
Glyburide—Visual impairment—Methotrexate—lymphatic system cancer	0.000246	0.00157	CcSEcCtD
Glyburide—Headache—Carmustine—lymphatic system cancer	0.000245	0.00157	CcSEcCtD
Glyburide—Eye disorder—Methotrexate—lymphatic system cancer	0.000239	0.00153	CcSEcCtD
Glyburide—Vomiting—Vincristine—lymphatic system cancer	0.000238	0.00152	CcSEcCtD
Glyburide—Rash—Vincristine—lymphatic system cancer	0.000236	0.00151	CcSEcCtD
Glyburide—Dermatitis—Vincristine—lymphatic system cancer	0.000236	0.00151	CcSEcCtD
Glyburide—Headache—Vincristine—lymphatic system cancer	0.000234	0.0015	CcSEcCtD
Glyburide—Nausea—Carmustine—lymphatic system cancer	0.000233	0.00149	CcSEcCtD
Glyburide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000232	0.00148	CcSEcCtD
Glyburide—Rash—Mitoxantrone—lymphatic system cancer	0.00023	0.00147	CcSEcCtD
Glyburide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000229	0.00147	CcSEcCtD
Glyburide—Headache—Mitoxantrone—lymphatic system cancer	0.000228	0.00146	CcSEcCtD
Glyburide—Alopecia—Methotrexate—lymphatic system cancer	0.000226	0.00144	CcSEcCtD
Glyburide—Erythema—Methotrexate—lymphatic system cancer	0.000222	0.00142	CcSEcCtD
Glyburide—Malnutrition—Methotrexate—lymphatic system cancer	0.000222	0.00142	CcSEcCtD
Glyburide—Nausea—Vincristine—lymphatic system cancer	0.000222	0.00142	CcSEcCtD
Glyburide—Nausea—Mitoxantrone—lymphatic system cancer	0.000216	0.00138	CcSEcCtD
Glyburide—Vision blurred—Methotrexate—lymphatic system cancer	0.00021	0.00134	CcSEcCtD
Glyburide—Anaemia—Methotrexate—lymphatic system cancer	0.000205	0.00131	CcSEcCtD
Glyburide—Leukopenia—Methotrexate—lymphatic system cancer	0.000199	0.00127	CcSEcCtD
Glyburide—Convulsion—Methotrexate—lymphatic system cancer	0.000193	0.00123	CcSEcCtD
Glyburide—Myalgia—Methotrexate—lymphatic system cancer	0.000189	0.00121	CcSEcCtD
Glyburide—Arthralgia—Methotrexate—lymphatic system cancer	0.000189	0.00121	CcSEcCtD
Glyburide—Confusional state—Methotrexate—lymphatic system cancer	0.000183	0.00117	CcSEcCtD
Glyburide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000178	0.00114	CcSEcCtD
Glyburide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000178	0.00114	CcSEcCtD
Glyburide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000175	0.00112	CcSEcCtD
Glyburide—Anorexia—Methotrexate—lymphatic system cancer	0.000173	0.00111	CcSEcCtD
Glyburide—Hypotension—Methotrexate—lymphatic system cancer	0.00017	0.00108	CcSEcCtD
Glyburide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000165	0.00106	CcSEcCtD
Glyburide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000163	0.00104	CcSEcCtD
Glyburide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000162	0.00103	CcSEcCtD
Glyburide—Dyspepsia—Methotrexate—lymphatic system cancer	0.00016	0.00102	CcSEcCtD
Glyburide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000158	0.00101	CcSEcCtD
Glyburide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000157	0.001	CcSEcCtD
Glyburide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00015	0.000957	CcSEcCtD
Glyburide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000148	0.000949	CcSEcCtD
Glyburide—Urticaria—Methotrexate—lymphatic system cancer	0.000144	0.000922	CcSEcCtD
Glyburide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000143	0.000918	CcSEcCtD
Glyburide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000134	0.000855	CcSEcCtD
Glyburide—Asthenia—Methotrexate—lymphatic system cancer	0.00013	0.000833	CcSEcCtD
Glyburide—Pruritus—Methotrexate—lymphatic system cancer	0.000128	0.000821	CcSEcCtD
Glyburide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000124	0.000794	CcSEcCtD
Glyburide—Vomiting—Methotrexate—lymphatic system cancer	0.000115	0.000738	CcSEcCtD
Glyburide—Rash—Methotrexate—lymphatic system cancer	0.000114	0.000732	CcSEcCtD
Glyburide—Dermatitis—Methotrexate—lymphatic system cancer	0.000114	0.000731	CcSEcCtD
Glyburide—Headache—Methotrexate—lymphatic system cancer	0.000114	0.000727	CcSEcCtD
Glyburide—Nausea—Methotrexate—lymphatic system cancer	0.000108	0.000689	CcSEcCtD
